MetaCap

AEON Biopharma (AEON) vs Aspire-Lakewood (ASBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aspire-Lakewood (ASBP) has outperformed AEON Biopharma (AEON) over the past year, gaining 83.8% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $10.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEON-85.18%ASBP+83.76%
+150%+21%-108%
Nov 21, 20251 yearNov 20, 2026
AEON-99.98%ASBP-98.27%
+64%-22%-108%
Jan 2, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEON versus ASBP key metrics
MetricAEONASBP
Share price$0.123$7.13
Market cap$10.35M$10.00M
1-day change-7.59%-5.44%
YTD return-88.82%+35.04%
1-year return-85.18%+83.76%
EPS (TTM)$-3.89$-30.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.20K
Net income (latest FY)$-39.22M$-24.48M
Gross margin—-1.87%
Operating margin—-312016.95%
Net margin—-394725.06%
52-week high$1.45$9.50
52-week low$0.106$0.11
Distance from 52-week high-91.52%-24.95%
Analyst consensusstrong_buy—
Avg. price target upside+1379.67%—
Average volume7.44M29.24K
Shares outstanding84.12M1.40M
Employees8—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ASBP has outperformed AEON by 168.9 percentage points over the past year.

About AEON Biopharma

AEON stock →

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Aspire-Lakewood

ASBP stock →

Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.

Health Care · Biotechnology: Pharmaceutical Preparations

AEON vs ASBP FAQ

Which is bigger, AEON Biopharma or Aspire-Lakewood?

AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $10.00M for Aspire-Lakewood (ASBP).

Which stock has performed better over the past year, AEON or ASBP?

ASBP returned +83.76% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.

Are AEON Biopharma and Aspire-Lakewood in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons